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SUMMARY 
Twelve subjects with a diagnosis of Obsessive Compulsive Disorder who had not shown response to amit-
ryptiline and imipramine/behaviour therapy underwent a cross over double blind trial with clomipramine and 
nortryptiline. Subjects who had earlier not shown response to the other drugs did not show response to clomip-
ramine. The implications of these findings for clinical management are discussed. 
Clomipramine has been widely recog-
nised as the drug of choice for obsessive 
compulsive disorder (OCD) whose effi-
cacy has been shown in various double 
blind studies (Thoren et al 1980, Marks et 
al 1980, Montgomery 1980, Ananth et al 
1981, Insel et al 1983). However, it has 
been suggested that about one third of pa-
tients do not respond to pharmacotherapy 
(Insel 1985). Higher cerebrospinal fluid 5-
hydroxy indole acetic acid has been shown 
to be related to clomipramine response 
(Thoren et al 1980b). Although various 
other drugs have been used (Insel & Mur-
phy 1981), current interest has focussed 
mainly on drugs acting on the serotonergic 
system. Drugs which have been found ef-
ficacious include the serotonin precursor 
L-tryptophan (Yarvura-Tobias & Bhaga-
van 1977) and serotonergic uptake in-
hibitors like zimeldine (Fontaine et al 
1985), trazodone (Prasad 1984) and 
Fluoxetine (Turner et al 1985). This in-
terest mainly steps from the serotonergic 
hypothesis of obsessive compulsive disor-
der (Yarvura-Tobias et al 1977) which has 
recently been questioned (Insel etal 1985). 
At a more pragmatic clinical plane, various 
issues remain unanswered. Although 
clomipramine has been suggested to have 
specific anti-obsessional properties 
(Mavissakalian & Michelson 1983) it is not 
available in various countries, such as 
India and U.S.A. In the absence of this 
drug, authors have suggested the use of im-
ipramine (Insel 1985) and amitryptiline 
(Snyder 1980) as the first line of therapy. 
Behaviour therapy has also got an estab-
lished role in the therapy of OCD, al-
though treatment failures here are also 
recognised (Steketee et al 1983). As such 
there remain a group of patients who do 
not respond to traditional tricyclic antidep-
ressants and behaviour therapy. In this 
study we have tried to study the efficacy of 
clomipramine in subjects who are non-re-
sponsive to other forms of therapy, as de-
fined here. 
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Materials and Methods 
The sample consisted of 18 subjects 
who had been followed up in the 
Psychiatry Out Patient Department at Na-
tional Institute of Mental Health and 
Neurosciences, Bangalore. The diagnosis 
was made according to DSM III (Ameri-
can Psychiatric Association 1980). Sub-
jects with depression were included in the 
OCD cohort provided (i) the depression 
was attributed by the subject as being sec-
ondary to the obsessive compulsive 
phenomenon (ii) there was a gap of atleast 
2 months between the onset of obsession 
and depression, with the former occuring 
first and (iii) there was no history sugges-
tive of melancholic or psychotic features 
(modified from Insel et al 1983). Non-re-
sponsiveness was defined as lack of sig-
nificant response to (i) 300 mg. of amit-
rytptiline daily for 6 weeks or (ii) imip-
ramine 300 mg. daily for 6 weeks. 
The subjects were allotted double 
blind to clomipramine and nortryptieline 
initially (10 to clomipramine, 8 to nor-
tryptiline). The drugs were administered 
in a dose of 50 mg/day for the first 3 days, 
with an increase of 50 mg/day every 3 days 
till the maximum tolerated dose or 200 mg/ 
day was reached. All subjects had been 
free of all psychotropic drugs for a period 
of 4 weeks before the onset of the study, 
with a similar gap between the last session 
of behaviour therapy and the onset of this 
trial. All subjects were rated weekly from 
the onset of the trial on a Side effects check 
list, Maudsley Obsessive Compulsive 
Questionniare (Hodgson & Rachman 
1977), Leyton's Obsessional Inventory 
(Cooper 1970) and Hamilton Depression 
Scale (Hamilton 1967). Each drug was 
given for a period of 6 weeks, with a cross 
over, with a drug free interval of 4 weeks. 
The blind was broken after the whole trial 
was over. Paired t' test was used to com-
pare groups before and after treatment. 
Results 
Out of the eighteen subjects with 
OCD, 8 completed the entire drug trial 
and 4 completed only one part of the trial. 
Of these 4, 3 completed the trial with 
clomipramine and 1 with nortryptilline. 
Six dropped out before finishing even one 
part of the trial. Thus 12 subjects received 
either drug for at least 6 weeks while 8 re-
ceived both. There were 4 female and 8 
male subjects. Two patients had only ob-
sessions while the others also had compul-
sions. 4 of these latter subjects were chec-
kers, 5 were washers and 1 had both check-
ing and washing compulsions. 
Pooling the data, 11 subjects received 
clomipramine and 9 nortryptiline. Seven 
of the subjects has received an adequate 
trail of amitryptiline (AMI) or imipramine 
(IMI). Nine of the 12 subjects received be-
haviour therapy (BT). Other interventions 
used included diazepam (DZM) and Elec-
troconvulsive therapy (ECT). The average 
age of consultation was 30 years 
(SD=7.92) and the mean duration of ill-
ness was 10.08 years (SD=7.22). The pa-
tients were classified according to the pre-
dominant symptom cluster present. 
There was no significant difference 
present between pre and post trial scores 
on the Leyton's Obsessional Inventory and 
Maudsley Obsessive Compulsive Ques-
tionnaire (Table 1). However there was a 
significant difference between the scores 
of Hamilton Depression Scale, but this did 
not differentiate between clomipramine 
and nortryptiline. Significant reduction of 
depressive symptoms was observed in both 
cases at 4 weeks. Only one of the 8 subjects 
who completed the whole trial reported 
subjective global improvement with 
clomipramine. 
When considering the scores before 
administration of any drug, there was no 
significant difference between the two CLOMIPRAMINE IN RESISTANT OBSESSIVE COMPULSIVE DISORDER 
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Table 1 
Changes in Depression and Obsessional Scores 
LOI : Symptom Score 
Trait Score 
Resistance Score 
Interference Score 
Maudsley Obsessional Questionnaire 
Hamilton Depression Scale 
Pre 
28.7 
13.2 
61.3 
66.2 
18.2 
18.9 
CLOMIPRAMINE 
(6.4) 
(3.1) 
(18.4) 
(23.1) 
(4.3) 
(5.4) 
Post 
25.4 
12.9 
56.8 
58.4 
18.4 
12.6 
(6.1) 
(2.8) 
(19.2) 
(26.1) 
(4.1) 
(7.9) * 
Pre 
31.3 
12.4 
56.4 
63.4 
17.4 
20.1 
NORTRYPTILINE 
(5.9) 
(3.3) 
(19.8) 
(21.8) 
(4.2) 
(6.5) 
Post 
27.8 
12.5 
52.4 
59.8 
17.1 
14.5 
(6.2) 
(2.9) 
(16.4) 
(19.6) 
(4.4) 
(9.2) * 
* P < .05  Standard Deviations are given in brackets 
groups who received nortryptiline (n=9) 
and clomipramaine (n=ll); there was also 
no difference between the group which 
completed atleast one part of the trial 
(n=12) and the group which did not (n=6) 
and the group which completed only one 
half of the trial (n=4). There was no statis-
tically significant difference when the anti-
obsessional effects of clomipramine and 
nortryptiline were compared, using either 
the 8 subjects who completed the whole 
trial or the 12 subjects who completed part 
of it. On the drug Side effects Check List, 
dryness of mouth was noted in 3 subjects 
who received clomipramine. Otherwise 
the drugs were well tolerated in the dosage 
regimen followed here. 
Discussion 
While clomipramine has been widely 
stated to be the drug of choice in OCD 
(Insel & Murphy 1981) there has been little 
stress on the drugs of choice where clomip-
ramine is not available. While admitting 
that about one third of patients do not re-
spond to clomipramine, Insel (1985) could 
not identify the non-responder group 
phenomenologically. He stated that the 
whole spectrum of obsessive compulsive 
disorders respond to clomipramine. Be-
haviour therapy is more beneficial when 
compulsions and avoiding are predomin-
ant (Insel 1985). Response to clomip-
ramine therapy has few predictors except 
for cerebrospinal fluid 5-hydroxy indole 
acetic acid levels (Thoren et al. 1980b). 
While amitryptiline has been found 
useful in OCD (Snyder 1980), some work-
ers have proposed imipramine as the first 
drug of choice because of its structural 
similarity to clomipramine (Insel 1985). A 
recent double blind study did not find 
much difference in the antiobsessional ef-
fects of imipramine and clomipramine 
(Volavka et al 1985). However in another 
study clomipramine was found superior to 
amitryptiline (Ananth et al 1981). 
The serotonergic hypothesis of OCD 
was initially proposed because of response 
to clomipramine, a serotonin uptake in-
hibitor, and L-tryptophan, a serotonin 
precursor (Yarvura-Tobias & Bhagavan 
1977). Support also came from lower cere-
brospinal fluid 5-hydroxy indole acetic 
acid levels found in OCD subjects (Thoren 
et al 1980b). More specific serotonin up-
take inhibitors have also been found effec-
tive (Prasad 1984, Fontaine et al 1985, 
Turner et al 1985). This hypothesis stresses 
that decreased serotonin is the cause for 
OCD. However our study identifies a sub-378  SUMANT KHANNA ET AL 
group of non-responders which apperantly 
does not have this biochemical abnor-
malty. Rather than disproving the 
serotonergic hypothesis our study stresses 
the need to study other neurotransmitter 
systems and points to the biochemical 
heterogenity of OCD. 
On a more pragmatic plane, subject 
who do not respond to amitryptiline or im-
ipramine in adequate doses, along with be-
haviour therapy, are unlikely to respond to 
clomipramine. One flaw in our study is the 
absence of plasma nor-tryptilline levels. 
With a maximum dose of 200 mg/day, 
some patients may have received doses 
outside the therapeutic window. There has 
been no study to the best of our knowledge 
where amitryptiline has been compared 
with imipramine. In a retrospective study 
where we studied sociodemographic and 
clinical factors (Khanna et al 1986a), im-
provement did not correlate with any 
specific modality of therapy. We are cur-
rently trying to develop alternate 
strategies of therapy of OCD. There is 
some suggestion that subjects with evi-
dence of cerebral damage or malfunction 
respond best to amphetamine (Khanna & 
Janakiramaiah 1984, Khanna submitted). 
An attempt is also being made to define 
predictors of outcome and therapy re-
sponse. This work is currently at a prelimi-
nary stage. However we have identified 
two large sub-groups of OCD probands. 
One consists of the young student, and the 
other a middle aged housewife (Khanna et 
al 1986b). We are trying to determine 
whether they have any preferred therapeu-
tic responsiveness. Finally, with responses 
of OCD to a wide range of drugs (Turner et 
al 1985), the possibility has also to be kept 
in mind that OCD is a heterogenous group 
of illnesses and separate sub-groups re-
spond better to specific therapies. Where 
anxiety is predominant alprazolam is effec-
tive (Tesar & Jenike 1984), while with 
panic attacks Monoamine Oxidase in-
hibitors may be the drug of choice (Jenike 
et al 1983). Some subjects who show ictal 
discharges respond to anti-epileptics 
(Jenike 1984) while ECT (Mellman & 
Groman 1984) and lithium (Stern & Jenike 
1983) also have been found useful. Most of 
the studies which have shown response to 
antipsychotics have not had clearly defined 
patient populations (Jenike 1983). 
Amitryptilline and imipramine when 
used in adequate doses for adequate 
periods of time most probably cover the 
therapeutic range for clomipramine, due 
to their serotonergic and noradr»nergic 
uptake inhibition. This study provides ten-
tative evidence that an adequate trial of 
imipramine and amitryptiline should be 
given in all cases of OCD, and that if sub-
jects do not respond to these two drugs, it 
is unlikely that they will show response to 
clomipramine. 
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